Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
35 employees
Rgenta Therapeutics develops oral, small-molecule RNA-targeting medicines for oncology and neurological disorders.
HQ
Founded
2018
Rgenta Therapeutics, founded with the mission to develop RNA-targeting medicines, focuses on creating oral, small-molecule treatments for oncology and neurological disorders. Utilizing a proprietary platform, Rgenta mines genomics data to identify targetable RNA processing events and designs small-molecule glues to modulate interactions among the spliceosome, regulatory proteins, and RNAs. This innovative approach aims to unlock the therapeutic potential of historically undruggable targets in human diseases.
Notable affiliated individuals include experts in genomics and drug development, contributing to the company's cutting-edge research. Rgenta has successfully raised $52 million in Series A financing, underscoring investor confidence in its potential. The company's pioneering work in RNA-targeting medicines has the potential to significantly impact the treatment landscape for previously incurable diseases, positioning Rgenta as a leader in the biopharmaceutical industry.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
RNA Medicines
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Rgenta Therapeutics founded?
Rgenta Therapeutics was founded in 2018.
Where is Rgenta Therapeutics's headquarters located?
Rgenta Therapeutics's headquarters is located in Cambridge, MA, US.
When was Rgenta Therapeutics's last funding round?
Rgenta Therapeutics's most recent funding round was for $8M (USD) in May 2023.
How many employees does Rgenta Therapeutics have?
Rgenta Therapeutics has 35 employees as of Feb 5, 2024.
How much has Rgenta Therapeutics raised to-date?
As of July 05, 2023, Rgenta Therapeutics has raised a total of $116.9M (USD) since May 8, 2023.
Add Comparison
Total Raised to Date
$116.9M
USD
Last Update May 8, 2023
Last Deal Details
$8M
USD
May 8, 2023
Series A
Current Employees
35
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts